TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)
Status:
Not yet recruiting
Trial end date:
2020-11-15
Target enrollment:
Participant gender:
Summary
A randomized parallel double-blinded placebo-controlled clinical trial to evaluate the effect
of Emtricitabine/Tenofovir alafenamide (FTC/TAF) compared with placebo on the risk of
developing SARS-CoV-2 disease (COVID-19) in healthcare workers with high transmission risk in
addition to currently recommended control measures.
Phase:
Phase 3
Details
Lead Sponsor:
Hospital Italiano de Buenos Aires
Collaborator:
Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)